Insider Selling: Alignment Healthcare (NASDAQ:ALHC) CEO Sells 73,046 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John Kao sold 73,046 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total value of $1,303,140.64. Following the completion of the sale, the chief executive officer directly owned 1,784,868 shares of the company’s stock, valued at $31,842,045.12. The trade was a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Alignment Healthcare Trading Down 0.2%

Shares of Alignment Healthcare stock traded down $0.03 on Thursday, reaching $18.16. The company had a trading volume of 3,987,587 shares, compared to its average volume of 3,191,394. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.71 and a quick ratio of 1.71. The firm’s 50-day moving average price is $20.57 and its two-hundred day moving average price is $18.78. Alignment Healthcare, Inc. has a 1 year low of $11.63 and a 1 year high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company earned ($0.16) earnings per share. Alignment Healthcare’s revenue was up 44.4% on a year-over-year basis. On average, research analysts anticipate that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ALHC shares. JPMorgan Chase & Co. increased their price objective on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. TD Cowen increased their price target on Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a report on Friday, January 16th. KeyCorp reissued an “overweight” rating and set a $28.00 price target on shares of Alignment Healthcare in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $24.56.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Recent analyst upgrades/price-target raises provide near-term support (UBS raised target to $21, Piper Sandler to $30, JPMorgan to $26), and the consensus target remains above the current price—helping underpin valuation.
• Positive Sentiment: Solid quarterly results: February quarter beat EPS and revenue estimates (revenue +44% YoY; EPS beat by $0.10), showing growth momentum in Medicare Advantage enrollment and monetization that supports longer-term upside.
• Neutral Sentiment: Zacks ran a comparison piece weighing ALHC vs. BrightSpring (BTSG) for value investors — useful context but not a company-specific catalyst. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Reported short-interest data is effectively zero/NaN in the recent reports (likely a reporting quirk); it doesn’t indicate a build of short pressure currently.
• Negative Sentiment: Cluster of insider sales from senior executives — President Dawn Maroney sold 30,000 shares (~$524k at $17.48) and other officers (Andreas P. Wagner, Robert L. Scavo) sold sizable blocks (~11k–12k shares each). Heavy insider selling can signal liquidity needs or personal diversification and often weighs on sentiment. Maroney sale filing: Maroney Form 4
• Negative Sentiment: Additional insider filings: Andreas P. Wagner sales (Form 4) and Robert L. Scavo sale (Form 4) were also disclosed, adding to the headline of insider liquidation. Wagner filing: Wagner Form 4 · Scavo filing: Scavo Form 4
• Negative Sentiment: Independent sell-side views: Weiss Ratings reiterated a “sell (D-)” and Wall Street Zen trimmed its rating to a hold — these dissenting views add downside risk if they influence broader investor sentiment. Weiss Ratings · Wall Street Zen reference included in company coverage.

Hedge Funds Weigh In On Alignment Healthcare

A number of institutional investors have recently modified their holdings of ALHC. Royal Bank of Canada boosted its holdings in shares of Alignment Healthcare by 92.6% in the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock valued at $1,720,000 after purchasing an additional 44,413 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Alignment Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock worth $1,109,000 after purchasing an additional 2,594 shares during the period. Goldman Sachs Group Inc. increased its holdings in Alignment Healthcare by 79.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock worth $18,112,000 after purchasing an additional 429,703 shares during the period. Woodline Partners LP bought a new stake in Alignment Healthcare during the 1st quarter valued at $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Alignment Healthcare by 16.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock worth $5,729,000 after buying an additional 44,452 shares during the period. 86.19% of the stock is owned by hedge funds and other institutional investors.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.